Seaport Research lowered the firm’s price target on Hims & Hers to $59 from $66 and keeps a Buy rating on the shares. Quarterly results showed solid growth trends despite near term headwinds, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Sell Rating Issued for Hims & Hers Health Amid Sluggish Subscriber Growth and Margin Pressures
- Hims & Hers price target raised to $32 from $28 at BofA
- Strong Buy Rating for Hims & Hers Health: Impressive Growth and Strategic Expansion Drive Future Potential
- Cautious Outlook Amid Strategic Expansion: Hold Rating for Hims & Hers Health
- Hims & Hers Stock (HIMS) Pops on Talks to Offer Novo Nordisk’s Wegovy